Quick 2015 Recap from another poster I thought was worth sharing:
September 8, 2015
First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD
September 3, 2015
Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer
September 1, 2015
Ocata Therapeutics Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa
August 31, 2015
Ocata Therapeutics Appoints Dr. Brian Levy to its Board of Directors
August 24, 2015
Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis
August 19, 2015
Ocata Therapeutics Secures $10 Million in Debt Financing
July 15, 2015
Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
July 14, 2015
Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus
July 1, 2015
Ocata Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
June 30, 2015
Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices
June 24, 2015
Ocata Therapeutics Announces Positive Results Reported in a Late Breaking Abstract at the Annual Meeting of the International Society for Stem Cell Research
June 18, 2015
Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015
June 16, 2015
Ocata Therapeutics Announces Pricing of $30 Million Offering of Common Stock and Warrants
June 2, 2015
Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases
May 26, 2015
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
May 18, 2015
Ocata Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
May 11, 2015
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
April 30, 2015
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
April 28, 2015
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science & Engineering Fair
March 31, 2015
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
March 24, 2015
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from Allele Biotechnology and Extends Leadership Position in Cell Therapy Capabilities
March 17, 2015
Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency
February 26, 2015
Ocata Therapeutics Approved for Listing on NASDAQ
February 25, 2015
Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology
February 24, 2015
Ocata Therapeutics to Present at 2015 Cowen Health Care Conference
February 11, 2015
Ocata Therapeutics Withdraws Offering of Common Stock
February 4, 2015
Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
February 3, 2015
Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
